Pan-Cancer Analysis Revealed SRSF9 as a New Biomarker for Prognosis and Immunotherapy

Table 1

The relationship between SRSF9 gene expression and the prognosis of different cancers in PrognoScan.

Gene	Dataset	Cancer type	Endpoint	Number	Cox value	HR	95% CI (low-high)
SRSF9	GSE1456-GPL97	Breast cancer	RFS	159	0.003805	3.91	1.55–9.86
SRSF9	GSE4922-GPL96	Breast cancer	DFS	249	0.007491	2.84	1.32–6.09
SRSF9	GSE4922-GPL96	Breast cancer	DFS	249	0.007793	2.52	1.28–4.99
SRSF9	GSE1456-GPL97	Breast cancer	DSS	159	0.012586	4.00	1.35–11.88
SRSF9	GSE31210	Lung cancer	RFS	204	0.027333	2.89	1.13–7.43
SRSF9	GSE9891	Ovarian cancer	OS	278	0.030832	1.70	1.05–2.74
SRSF9	GSE8970	Blood cancer	OS	34	0.030936	3.98	1.14–13.95
SRSF9	GSE1456-GPL96	Breast cancer	DSS	159	0.031512	3.03	1.10–8.32
SRSF9	HARVARD-LC	Lung cancer	OS	84	0.033228	2.84	1.09–7.42
SRSF9	GSE4922-GPL97	Breast cancer	DFS	249	0.034675	2.05	1.05–4.00
SRSF9	GSE19234	Skin cancer	OS	38	0.035679	4.31	1.10–16.84
SRSF9	GSE11595	Esophagus cancer	OS	34	0.036602	2.33	1.05–5.15
SRSF9	GSE1456-GPL96	Breast cancer	RFS	159	0.039336	2.51	1.05–6.00
SRSF9	GSE1456-GPL97	Breast cancer	OS	159	0.043242	2.58	1.03–6.47
SRSF9	GSE17710	Lung cancer	RFS	56	0.044264	2.48	1.02–6.02
SRSF9	GSE3494-GPL96	Breast cancer	DSS	236	0.046057	2.40	1.02–5.66